Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

Tvardi Therapeutics was founded by Dr. David Tweardy, an oncologist and researcher at the University of Texas MD Anderson Cancer Center, based on his work on STAT3 signaling. The company operates as a Delaware corporation with its principal office in Houston, Texas, as disclosed in SEC filings. The firm focuses on developing oral small-molecule inhibitors of STAT3, a protein that regulates genes involved in cell proliferation and survival. TTI-101, its lead asset, is in Phase 2 clinical trials for multiple cancer types, including hepatocellular carcinoma and idiopathic pulmonary fibrosis. The company lists oncology and inflammatory disease as primary therapeutic areas (per SEC filings, 2022). Tvardi has raised at least $124 million in equity financing since its inception, including a $74 million Series B round announced in June 2022. Investors in that round include Fidelity Management & Research Company, OrbiMed Advisors, and the Cancer Prevention and Research Institute of Texas (CPRIT). The company does not disclose AUM or deployment figures in a family-office context, as its fundraising is conducted through private placements. A structural differentiator is Tvardi's exclusive focus on STAT3, a target historically considered undruggable, which positions the firm in a niche with limited competition. The company's academic roots at MD Anderson provide a translational research pipeline, though it has not yet disclosed a succession or governance structure typical of family offices.